← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2005Last known activity
Mar 2, 2021
Timeline
2000s
- Jun 1, 2005
Ziopharm— Founded
Drugs by trial phase (29 distinct, 41 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Indications
Studied for
- Bone Marrow Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Germinoma
- Glioblastoma
- Glioma
- Hematologic Neoplasms
- Leukemia
- Leukemia, Biphenotypic, Acute
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoproliferative Disorders
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm, Residual
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Plasma Cell
- Osteosarcoma
- Ovarian Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Sarcoma
- Seminoma
- Small Cell Lung Carcinoma
- Teratoma
- Testicular Neoplasms
- Thymoma
Recent trials (50)
- NCT04844086Lead sponsorPhase 1Mar 2, 2021
- NCT04006119Lead sponsorPhase 2Jun 28, 2019
- NCT04006119Study directorPhase 2Jun 28, 2019
- NCT03579888CollaboratorPhase 1Jan 31, 2019
- NCT03679754Lead sponsorPhase 1Sep 30, 2018
- NCT03679754Study directorPhase 1Sep 30, 2018
- NCT03636477Study directorPhase 1Jun 18, 2018
- NCT03636477Lead sponsorPhase 1Jun 18, 2018
- NCT03330197Study directorPhase 1Sep 26, 2017
- NCT03330197Lead sponsorPhase 1Sep 26, 2017
- NCT02529813CollaboratorPhase 1Dec 1, 2015
- NCT02026271Lead sponsorPhase 1Jun 1, 2015
- NCT02026271Study directorPhase 1Jun 1, 2015
- NCT02423902Study directorPhase 1/Phase 2Apr 1, 2015
- NCT02423902Lead sponsorPhase 1/Phase 2Apr 1, 2015
Details
- Founded
- New York, NY, US Jun 1, 2005
- Last known activity
- Mar 2, 2021